<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402686</url>
  </required_header>
  <id_info>
    <org_study_id>ML29719</org_study_id>
    <nct_id>NCT02402686</nct_id>
  </id_info>
  <brief_title>Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)</brief_title>
  <acronym>SIMPACT</acronym>
  <official_title>Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The aim of this non-interventional study in Hungarian participants is to gather real life
      data about the efficacy and safety of tocilizumab SC monotherapy in RA, to assess data about
      pattern of usage of tocilizumab monotherapy in RA disease management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2015</start_date>
  <completion_date type="Anticipated">February 26, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Disease Activity Score 28 (DAS28) from Baseline to End of Study</measure>
    <time_frame>Baseline, end of study (up to 24 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Disease Activity Index (CDAI) Score from Baseline to End of Study</measure>
    <time_frame>Baseline, end of study (up to 24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28 Remission, as Defined by DAS28 Less Than or Equal to (≤) 2.6</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CDAI Remission, as Defined by CDAI ≤2.8</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 from Baseline to End of Study in Different Monotherapy Subgroups</measure>
    <time_frame>Baseline, end of study (up to 24 weeks)</time_frame>
    <description>The following 3 monotherapy subgroups will be included: 1) participants starting tocilizumab after failing disease-modifying antirheumatic drugs (DMARDs), 2) participants starting tocilizumab after failing one biologic, 3) participants starting tocilizumab after failing two or more biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28 Remission in Different Monotherapy Subgroups, as Defined by DAS28 ≤2.6</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The following 3 monotherapy subgroups will be included: 1) participants starting tocilizumab after failing DMARDs, 2) participants starting tocilizumab after failing one biologic, 3) participants starting tocilizumab after failing two or more biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tocilizumab SC Injections per Participant During Observational Treatment Period</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Tocilizumab, Categorized by the Reasons for the Discontinuations</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on SC Tocilizumab First Line Monotherapy</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Reasons for SC Tocilizumab Monotherapy</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Treated Previously with a Tumor Necrosis Factor (TNF) Inhibitor/Other Biologic and Low Dose Methotrexate (Less Than 10 Milligrams/Week)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Other DMARDs Than Methotrexate Before Tocilizumab Monotherapy Initiation and at End of Observation Period</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Oral Steroid at Initiation of Tocilizumab SC Therapy and at End of Study</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Steroid Dose Reductions/Withdrawal at End of Observation Period</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Steroid Tapering in Different Monotherapy Subgroups Who Achieved DAS28 Remission</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The following 3 monotherapy subgroups will be included: 1) participants starting tocilizumab after failing DMARDs, 2) participants starting tocilizumab after failing one biologic, 3) participants starting tocilizumab after failing two or more biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab for RA in Routine Clinical Practice</arm_group_label>
    <description>Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.</description>
    <arm_group_label>Tocilizumab for RA in Routine Clinical Practice</arm_group_label>
    <other_name>RoActemra</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants receiving treatment for RA with tocilizumab SC according to standard of care
        and in line with the current SPC/local labeling and who have no contraindication to
        tocilizumab therapy as per the local label. This can include participants who have received
        tocilizumab SC monotherapy treatment within 8 weeks prior to the enrollment visit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and
             European League Against Rheumatism (EULAR) joint criteria

          -  Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under
             the prescriptive authority of a physician who has made the decision to commence
             tocilizumab in accordance with the local label

          -  Methotrexate intolerance, or inadequate response to prior DMARDs and TNF inhibitors
             where continued methotrexate treatment was deemed inappropriate

        Exclusion Criteria:

          -  Treatment with tocilizumab more than 8 weeks prior to enrollment

          -  Failure to meet local tocilizumab label indication criteria

          -  Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC
             monotherapy

          -  Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy

          -  History of any other autoimmune or joint inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML29719 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Rheumatology and Physiotherapy; 4Th Rheumatology Department</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Kórház KHT. II. Reumatológia</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Honved Korhaz, Reumatologia</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- és Egészségtudományi Centrum; Belgyógyászati Intézet, Reumatológiai Tanszék</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Hospital; Dep. of Rheumatology</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vaszary Kolos Kórház</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman Hospital; Dept. of Infectious Diseases</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Petz Aladár County Teaching Hospital</name>
      <address>
        <city>Győr</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szent Andras Reumakorhaz; Reumatologia</name>
      <address>
        <city>Heviz</city>
        <zip>8380</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2084</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szent Ferenc Kórház; Reumatológia</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Josa Andras Korhaz; Reumatologia</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinikai Központ: Immunológiai és Reumatológiai Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Aok Szent-Gyorgyi Albert Klinikai Kozpont; Rheumatologiai Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6724</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fejér Megyei Szent György Kórház; Reumatológiai Osztály</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Markusovszky Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veszprém Megyei Csolnoky Ferenc Kórház; Reumatológia</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

